H.W. Reesink MD PhD

Associate professor (UHD)
Main activities
Internist / Hepatologist
Focus of research

Viral Hepatitis

Key publications
  • Reesink HW, Fanning GC, Farha KA, Weegink C, van Vliet A, van 't Klooster G, Lenz O, Aharchi F, Mariën K, van Remoortere P, de Kock H, Broeckaert F, Meyvisch P, van Beirendonck E, Simmen K, Verloes R, Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. GASTROENTEROLOGY 2010;138 (3):913-921 [PubMed]
  • McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM [Contributors: Heathcote EJ, Kaita K, Ma M, Myers R, Sherman M, Yoshida E, Berg T, Manns MP, Zeuzem S, de Knegt R, Reesink HW, van Hoek B, Afdhal NH, Arora S, Bernstein D, Cochran J, Di Bisceglie AM, Dickson R, Dieterich DT, Etzkorn K, Everson GT, Faruqui S, Ghalib R, Gitlin N, Godofsky E, Gordon S, Hassanein T, Jacobson IM, Kilby A, Kugelmas M, Kwo PY, Lawitz ES, Lindsay K, Maillard M, Nelson DR, Nyberg L, Patel K, Muir AJ, Poordad FF, Rodriguez-Torres M, Rustgi V, Schiff E, Shaikh O, Sherman KE, Shiffman ML, Smith J, Strohecker J, Sulkowski MS, te H, Terrault NA, Vierling J, Wruble L, Younossi ZM, Zein N]] , Telaprevir for previously treated chronic HCV infection. NEW ENGL J MED 2010;362 (14):1292-1303 [PubMed]
  • Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van Vliet A, van de Wetering de Rooij J, McNair L, Purdy S, Kauffman R, Alam J, Jansen PLM, Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. GASTROENTEROLOGY 2006;131 (4):997-1002 [PubMed]
  • van der Poel CL, Reesink HW, Lelie PN, Leentvaar-Kuypers A, Choo QL, Kuo G, Houghton M, Anti-hepatitis C antibodies and non-A, non-B post-transfusion hepatitis in The Netherlands. LANCET 1989;334 (8658):297-298 [PubMed]
  • Wong VC, Ip HM, Reesink HW, Lelie PN, Reerink-Brongers EE, Yeung CY, Ma HK, Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. LANCET 1984;323 (8383):921-926 [PubMed]
All Publications
Current research funding
  • Accelsiors Ltd.
  • Gilead Sciences, Inc.
  • Medical Research BV